MTOR and breast cancer: The first IHC analysis was performed on the samples of invasive BC patients (20 patients) (Figure 1a) and showed a prevalence of high PI3K expression (score of 3+ in 55% of cases) (Figure 1a,b) with mTOR over-expression in 45% of cases.